Literature DB >> 27777157

Gamma Knife Radiosurgery for Residual and Recurrent Vestibular Schwannomas After Previous Surgery: Clinical Results in a Series of 90 Patients and Review of the Literature.

Michele Bailo1, Nicola Boari2, Filippo Gagliardi1, Alberto Franzin1, Martina Piloni1, Alfio Spina1, Marco Gemma3, Antonella Del Vecchio4, Angelo Bolognesi5, Pietro Mortini6.   

Abstract

OBJECTIVE: Complete removal of vestibular schwannomas (VS) is not always achievable without any risk of disabling postoperative complications, especially in terms of facial nerve function. Moreover, even after gross total removal, a relevant rate of recurrence has been reported. The aim of this study is to validate Gamma Knife radiosurgery (GKRS) as an effective strategy to treat tumor regrowth after previous surgery.
METHODS: Ninety patients treated with GKRS for VS after previous microsurgery were included in the present study. GKRS was performed at a median of 31 months (range, 4-174 months) postoperatively. Mean tumor volume was 3.35 cm3 (median, 2.5 cm3; range, 0.027-13 cm3) and median marginal dose was 13 Gy.
RESULTS: At a mean follow-up of 77.2 months, tumor control was achieved in 90% of patients: 2 patients underwent repeated GKRS, and 7 patients underwent further microsurgery. Tumor shrinkage at last follow-up was recorded in 80.3% of cases. The complication rate was low and many consisted of a transient worsening of preexisting symptoms. The overall incidence of persisting facial nerve deficit and trigeminal nerve impairment was, in both cases, 3.3%. Two of 5 patients (40%) preserved functional hearing at last follow-up. One patient (1.1%) underwent ventriculoperitoneal shunting 12 months after GKRS.
CONCLUSIONS: GKRS is a safe and effective treatment for growing residual and recurrent VSs, with tumor control obtained in 90% of cases and a low morbidity rate. Moreover, the possibility of treating patients with major medical comorbidities constitutes a significant advantage over repeated surgery.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acoustic neuroma; Gamma Knife; Previous surgery; Radiosurgery; Recurrent; Regrowth; Residual; Review; Vestibular schwannoma

Mesh:

Year:  2016        PMID: 27777157     DOI: 10.1016/j.wneu.2016.10.066

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  6 in total

1.  Communicating hydrocephalus after radiosurgery for vestibular schwannomas: does technique matter? A systematic review and meta-analysis.

Authors:  Paolo De Sanctis; Sheryl Green; Isabelle Germano
Journal:  J Neurooncol       Date:  2019-10-16       Impact factor: 4.130

2.  Optimal Volume of the Residual Tumor to Predict Long-term Tumor Control Using Stereotactic Radiosurgery after Facial Nerve-preserving Surgery for Vestibular Schwannomas.

Authors:  Won Jae Lee; Jung Il Lee; Jung Won Choi; Doo Sik Kong; Do Hyun Nam; Yang Sun Cho; Hyung Jin Shin; Ho Jun Seol
Journal:  J Korean Med Sci       Date:  2021-04-26       Impact factor: 2.153

3.  Surgery After Surgery for Vestibular Schwannoma: A Case Series.

Authors:  Łukasz Przepiórka; Przemysław Kunert; Wiktoria Rutkowska; Tomasz Dziedzic; Andrzej Marchel
Journal:  Front Oncol       Date:  2020-12-18       Impact factor: 6.244

4.  Long-term outcomes of rotating gamma knife for vestibular schwannoma: A 4-year prospective longitudinal study of 89 consecutive patients in Vietnam.

Authors:  Hung Dinh Kieu; Duong Ngoc Vuong; Khoa Trong Mai; Phuong Cam Pham; Tam Duc Le
Journal:  Surg Neurol Int       Date:  2021-11-30

Review 5.  Stereotactic radiosurgery for vestibular schwannomas.

Authors:  Steve Braunstein; Lijun Ma
Journal:  Cancer Manag Res       Date:  2018-09-20       Impact factor: 3.989

6.  Quantitative Evaluation of Proliferative Potential Using Flow Cytometry Reveals Intratumoral Heterogeneity and Its Relevance to Tumor Characteristics in Vestibular Schwannomas.

Authors:  Soichi Oya; Shinsuke Yoshida; Shunya Hanakita; Mizuho Inoue
Journal:  Curr Oncol       Date:  2022-03-03       Impact factor: 3.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.